DAY 1
Friday
24 Feb 2023
10:30-11:30 am
Inauguration of the 20th BioAsia Convention by:
Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, Government of Telangana
Guests of Honour:
Dr. VK Paul, Hon'ble Member (Health), NITI Aayog
Dr. Vas Narasimhan, CEO, Novartis
Mr. Jayesh Ranjan IAS, Principal Secretary (I&C), Govt of Telangana
12:00-1:30 pm
- Importance of cross-sectoral collaboration: what are the expectations from each part of the ecosystem (what role are they expected to play/what contribution can they make)?
- What policy enablement would encourage 'One Health' approach?
- How to operationalize the 'One Health' approach in India?
Panelists:
Chair: Dr. VK Paul, Hon'ble Member (Health), NITI Aayog
- Dr. Richard Hatchett, CEO, CEPI, UK
- Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, Bristol Myers Squibb, USA
- Ms. Cynthia McCaffrey, UNICEF Representative to India
- Dr. Mahender Nayak, Head of Asia Pacific, Takeda Pharmaceuticals, Singapore
- Dr. Sai D. Prasad, Executive Director, Bharat Biotech International Ltd.
Moderator: Dr. Gagandeep Kang, Virologist and Professor, Dept. of Gastrointestinal Sciences, CMC Vellore
1:30–2:30 pm
2:30–3:45 pm
- Where are we on our journey of achieving Universal Healthcare (recognizing the success thus far, discussing future action plan)?
- How can we strengthen the healthcare infrastructure/resources availability (personnel and physical)?
- What role can digital/ technology and data (e.g. real world data) play in improving healthcare access and outcome?
- How can we increase focus on preventive healthcare in India (insurance, awareness in masses, behavior/mindset of population and healthcare system, focus on nutrition for all)?
- What new innovative and sustainable financing mechanisms can be explored?
- Global best practices/case studies on use of digital, improving patient awareness/experience, innovative financing mechanisms, and achieving Universal Healthcare.
- Dr. Basant Garg IAS, Additional CEO, National Health Authority (NHA)
- Dr. Shyam Bishen, Head, Shaping the Future of Health and Healthcare, Member of Executive Committee, World Economic Forum
- Prof. K. Srinath Reddy, Honorary Distinguished Professor and Goodwill Ambassador, Public Health Foundation of India
- Mr. Annaswamy Vaidheesh, CEO, North star Asia LLP
- Dr. Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures
- Mr. Uday Bose, Head of Human Pharma Global Go-To-Market and Business Steering, Boehringer Ingelheim, Germany
- Mr. Simpson Emmanuel, CEO & Managing Director, Roche Pharma India
Moderator: Mr. Vikas Dandekar, Editor - Pharma and Life Sciences, ET Prime
3:50–4:45 pm
- Changes in patient’s journey/healthcare experience due to digital technology?
- Next generation remote health care models: home healthcare, virtual clinics (healthcare anywhere, anytime)?
- Metaverse – new possibilities and realities?
- Mr. Agam Upadhyay, SVP, Chief Technology Officer, GSK, USA
- Mr. Philippe Houben, Head of GTM and Digital transformation - IMETA, Boehringer Ingelheim, UAE
Moderator: Mr. Ram Deshpande, Partner, Digital Transformation, EY
4:45–5:45 pm
6:10-7:30 pm
India continues to strengthen its foothold in the pharmaceutical industry – country’s leadership in generics was established long back, and COVID vaccines demonstrate industry’s success in rapid innovation capabilities.
What could drive the future growth for Indian pharmaceutical industry?
- China plus one opportunity
- Overcoming the uncertainty of global markets
- Encouraging policy for enabling innovation and self-sustenance in KSMs and API (e.g., research linked incentives/RLI)
- Further strengthen presence in biosimilars market
- Contextualizing new areas (e.g. mRNA technology, CAR-T) to India and emerging markets
Chair: Mr. KT Rama Rao, Hon. Minister of I&C, Government of Telangana
- Mr. Satish Reddy, Chairman, Dr. Reddy’s Laboratories
- Mr. Ajay Piramal, Chairman, Piramal Group
- Ms. Mahima Datla, Managing Director, Biological E Ltd.
- Mr. Glenn Saldanha, MD and CEO, Glenmark Pharmaceuticals
- Mr. Hari S Bhartia, Founder and Co-Chairman, Jubilant Bhartia Group
Moderator: Ms. Shereen Bhan, Managing Editor, CNBC-TV18
CEO Conclave Sponsor
7:30 pm
Business cocktail parties are a great opportunity to break out of your shell.
DAY 2
Saturday
25 Feb 2023
10:30-11:15 am
Dr. Sumbul Desai, VP Health, Apple, USA
Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, India
11:20-12:25 pm
- Benefits of using data analytics and technology across the R&D process, i.e. drug discovery to clinical trials (improved productivity and efficiency)
- Potential of new technology platforms, e.g. cell & gene therapy, stem cell therapy, CRISPR, oncolytic viruses, RNAi
- Success stories and challenges from Indian industry
- Global best practices in R&D to develop, manufacture and supply innovative medicines
- Importance of partnerships and collaborations
- Opportunities for India pharma industry (including small biotechs and CRO)
- Dr. S. Chandrasekhar, Secretary to the Government of India, Department of Science & Technology
- Mr. Sauri Gudlavalleti, COO, Sai Life Sciences
- Dr. Christine Durinx, Managing Director, VIB, Belgium
- Mr. Mahesh Bhalgat, COO, Syngene
- Dr. Arun Anand, COO, Immuneel Therapeutics
- Prof. Rahul Purwar, Associate Professor – IIT Bombay, CEO & Founder, ImmunoACT
Moderator: Dr. Narendra Chirmule, Founder-director, SymphonyTech Biologics
Co-moderator: Ms. Anju Ghangurde, Executive Editor, Scrip
Session Sponsor
12:30-1:30 pm
- What challenges we face today in India regarding drug and device quality/quality perception?
- What have we done to increase focus on drug and devices quality and how successful have we been?
- What more needs to be done?
- What are the real issues and how can we address those (e.g., infrastructure and people/training/culture investments to establish right quality frameworks, and establish quality by design?)
- Will digital transformation help?
- What other urgent initiatives do we need to take?
- Mr. Mark Abdoo, Associate Commissioner for Global Policy and Strategy, US FDA
- Dr. Carmelo Rosa, Director, Division of Drug Quality, CDER, US FDA
- Dr. Sarah McMullen, Country Director - India, FDA
- Prof. Sarfaraz K. Niazi, Adj. Professor of Pharmaceutical Sciences, University of Illinois, Chicago, USA
- Mr. Ian White, Executive Director, NSF Health Sciences and Former GMDP Inspector, MHRA UK
- Mr. Pavan Kumar Mocherla, EVP & President Greater Asia, BD
- Mr. Michael Cutter, Chief Quality Officer, Biocon Biologics Ltd.
Moderator: Ms. Ekta Batra, Anchor & Associate Editor Research, CNBC-TV18
2:30–3:30 pm
- India has been strong in frugal innovation as also evidenced by some innovative COVID diagnostics: how can India continue to build strength?
- Digital therapeutics (e.g. sensor and AI-based diagnostics and treatment) – with the inherent IT strength, how can India make it big in this space?
- When and how will India foray into complex and innovative medical devices?
- What are the regulatory transformation requirements?
- Mr. Michael Blackwell, Vice President & Managing Director – India, Medtronic
- Mr. Bhargav Kotadia, MD, Sahajanand Medical Technologies Ltd.
- Mr. Shishir Agarwal, Managing Director, Terumo India Pvt. Ltd.
- Mr. Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD)
- Mr. Nikhil Srivastava, Managing Director, PAG
Session Sponsor
3:35–4:35 pm
Globally, all healthcare systems are moving towards Integrated healthcare to improve overall health outcomes for patient and reduce healthcare costs.
- Tech industry will contribute to next-generation health and the new interplay of strategic partnerships, advanced technologies, and data strategies in health care.
- Interoperability is a very important requirement for integrated healthcare systems – what is the plan to ensure this?
- What regulatory and policy interventions will be required for the entire ecosystem to work collaboratively, while keeping patients at the center?
- How can technology enable providing healthcare in the hinterland? Is it easier to start integrated healthcare in the hinterland?
- How will technology enable in drug registry and create measures to tackle counterfeit drugs?
- Mr. Jayesh Ranjan IAS, Principal Secretary, Dept. of Industries & Commerce, Government of Telangana
- Dr. Ramesh Byrapaneni, Managing Director, Endiya Partners
- Mr. Jason Mitakidis, Founder, Cyclica and HealthWorks, Canada
- Mr. Max Narr, CEO, Endosane Pharmaceuticals GmbH and Chief Investment Officer, Sanity Group, Germany
- Mr. Alok Joshi, CEO, ABCD Technologies
- Mr. Sanjeev Malhotra, CEO, Centre of Excellence for IOT & AI, NASSCOM
Moderator: Mr. Suresh Subramanian, Partner and National Life Sciences Leader, EY
4:40-5:40 pm
- Where are we two years post COVID? How much did India actually benefit from China Plus One strategy?
- What further investments are required?
- What regulatory and government support is needed?
- What role can technology play?
- ESG/Sustainability enablement practices in relation to manufacturing/supply chain? Adopting ESG as a culture
- Ms. S Aparna IAS, Secretary to the Government of India, Department of Pharmaceuticals
- Mr. Manni Kantipudi,CEO,Aragen Life sciences
- Mr. Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines Ltd.
- Mr. Suresh Pattathil, President OPPI and MD Abbvie, India
- Mr. Narendra Otsawal, MD, Warburg Pincus
Moderator: Mr. Satish Reddy, Chairman, Dr. Reddy’s Laboratories
5:45-6:45 pm
Chief Guest: Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, Government of Telangana
7:00 pm
DAY 3
Sunday
26 Feb 2023
10:30–1:00 pm